KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EBITDA (2016 - 2025)

Historic EBITDA for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to -$37.9 million.

  • Pacific Biosciences Of California's EBITDA rose 3546.01% to -$37.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$504.8 million, marking a year-over-year decrease of 2914.82%. This contributed to the annual value of -$309.6 million for FY2024, which is 261.71% down from last year.
  • According to the latest figures from Q3 2025, Pacific Biosciences Of California's EBITDA is -$37.9 million, which was up 3546.01% from -$42.0 million recorded in Q2 2025.
  • In the past 5 years, Pacific Biosciences Of California's EBITDA ranged from a high of $16.6 million in Q3 2021 and a low of -$426.1 million during Q1 2025
  • Moreover, its 5-year median value for EBITDA was -$72.8 million (2022), whereas its average is -$85.1 million.
  • Over the last 5 years, Pacific Biosciences Of California's EBITDA had its largest YoY gain of 16954.64% in 2021, and its largest YoY loss of 689456.1% in 2021.
  • Quarter analysis of 5 years shows Pacific Biosciences Of California's EBITDA stood at -$70.4 million in 2021, then decreased by 17.67% to -$82.9 million in 2022, then grew by 3.53% to -$80.0 million in 2023, then surged by 101.55% to $1.2 million in 2024, then crashed by 3152.58% to -$37.9 million in 2025.
  • Its last three reported values are -$37.9 million in Q3 2025, -$42.0 million for Q2 2025, and -$426.1 million during Q1 2025.